Plastic Product manufacturer Tarsons Products announced Q2FY23 results: Revenue for Q2FY23 stood at Rs 71.2 crore as compared to Rs 76.0 crore in Q2FY22 The dip in the revenue was on account of the high share of covid related revenues during H1FY22 EBIDTA for Q2FY23 stood at Rs 32.7 crore as compared to Rs 38.5 crore in Q2FY22 EBIDTA margins have been impacted on account of manpower costs for upcoming facility & Marketing & Branding expenses in the exports markets to fuel future growth engines Commenting on the Q2FY23 performance of the company, Rohan Sehgal said: “Our revenues for Q2FY23 were down by 6% on a YoY basis and up by 4% on a QoQ basis. If we compare on a like-to-like basis, i.e. negating the high base of covid related revenues in H1FY22, our conventional business has shown substantial growth. In addition, our product portfolio and a wide network of distributors across India. We are confident of sustaining our growth in the domestic conventional business. Our export revenues have grown by 11% & 12% for Q2 & H1FY23 respectively. With expanding product portfolio and the Brand & Trust, Tarsons has developed over the last four decades. We are confident of expanding our footprints in the global markets. Our capacity expansion is on track and the commissioning of the upcoming facility is expected to be in H1FY24. We are confident of ramping up this facility in a short span because Tarsons as a brand has grown in popularity for quality products and timely delivery. Our strategy is to be present in all business segments of the life science industry, gain a significant share of the Indian market, and strengthen our presence in the export markets.” Result PDF
Plastic products firm Tarsons Products announced Q1FY23 Result : Q1FY22 i.e. April to June 2021 witnessed higher share of sales on account of second wave of Covid. The Revenue contribution from conventional business in Q1FY22 was lower due to the demand from other life science industry on account of lockdowns and reduced activities. Q1FY23 witnessed a normalized quarter with healthy growth and higher contribution from conventional business. On a like-to-like basis, our conventional business has witnessed YoY growth. Gross margin in Q1FY23 was impacted due to change in product mix and inflationary commodity environment on account of geo political tensions and supply chain disruptions. EBIDTA margins in Q1FY23 were also impacted on account of higher expenses due to traveling and participation in fare & exhibitions and higher investments in manpower to support future growth. Commenting on the Q1 FY23 performance of the company Mr. Rohan Sehgal Said: “Revenue for Q1FY23 was muted on account of higher share of Covid related revenues which contributed significantly in Q1FY22. However, despite negligible contribution from covid related revenues in Q1FY23 your company has been able to deliver revenues at par on Y-o-Y basis. We have been participating in various fare & exhibitions in the exports markets to mark our presence as a leading suppliers of labware products of global standards and quality. We have been receiving positives responses & enquires and are optimistic of higher demand from international markets going forward. Our expansion of new facilities is on track and progressing well, we believe with the new facilities, addition of new product portfolio and trusted brand for “TARSONS” in the life science community, we are optimistic about the new phase of growth of your company. Our focus remains on brand building, deliver quality products, automation of processes and improve export presence and we continue to work in that direction.” Result PDF
Plastic Products company Tarsons Products declares Q3FY22 result: Q3FY22 : Revenue from Operations Rs. 71 crores Gross Profit Rs. 55 crores EBIDTA Rs. 33 crores Profit after Tax Rs. 22 crores Revenue contribution from exports has increased from 31% in Q3FY21 to 41% in Q3FY22 9MFY22 : Revenue from Operations Rs. 216 crores Gross Profit Rs. 172 crores EBIDTA Rs. 108 crores Profit after Tax Rs. 71 crores Commenting on the Q3 & 9MFY22 performance of the company Mr. Rohan Sehgal Said: “We are delighted to post strong revenue & profitability growth for Q3 & JMFY22 on the back of strong demand for our products across the end user industry. Revenue for 9WFY22 grew by 34% and PAT for 9MFY22 grew by 57% on YoY basis. Our domestic business witnessed strong momentum with demand for our products and wallet share addition across customers increasing on month on month basis. Our export business also grew by ~42% for 9MFY22 as compared to the same period last year. Going forward, we are optimistic of the demand scenario from the domestic and the overseas market and our product diversification strategy coupled with addition of wallet share from the existing customers helps us to maintain a positive outlook on the revenue growth and profitability. Our expansion plans with new facility and upgradation of capabilities in the existing plants is on track and should be operational by middle of FY23 At Tarsons, we believe in Trust & Quality which will help us to capture higher market share in the growing plastic labware market Moving forward, we also reiterate our confidence in our ability to sustain Company’s delivery of outstanding shareowner value” Result PDF
Pre-IPO Conference Call with Tarsons Products Ltd. Management and Analysts on Company Performance and Outlook. Listen to the full transcript.